FR3048286B1 - Peptides immunogenes et leur utilisation - Google Patents

Peptides immunogenes et leur utilisation Download PDF

Info

Publication number
FR3048286B1
FR3048286B1 FR1651610A FR1651610A FR3048286B1 FR 3048286 B1 FR3048286 B1 FR 3048286B1 FR 1651610 A FR1651610 A FR 1651610A FR 1651610 A FR1651610 A FR 1651610A FR 3048286 B1 FR3048286 B1 FR 3048286B1
Authority
FR
France
Prior art keywords
peptides
value
formation
ratio
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1651610A
Other languages
English (en)
Other versions
FR3048286A1 (fr
Inventor
Pierre-Alain Rubbo
Edouard Tuaillon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Omunis
Universite de Montpellier I
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Montpellier CHUM
Universite de Montpellier
AxLR SATT du Languedoc Roussillon SAS
Original Assignee
Omunis
Universite de Montpellier I
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Montpellier CHUM
Universite de Montpellier
AxLR SATT du Languedoc Roussillon SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1651610A priority Critical patent/FR3048286B1/fr
Application filed by Omunis, Universite de Montpellier I, Institut National de la Sante et de la Recherche Medicale INSERM, Centre Hospitalier Universitaire de Montpellier CHUM, Universite de Montpellier, AxLR SATT du Languedoc Roussillon SAS filed Critical Omunis
Priority to PCT/FR2017/050418 priority patent/WO2017144830A1/fr
Priority to EP17712193.6A priority patent/EP3420358A1/fr
Priority to CN201780013116.0A priority patent/CN108885213A/zh
Priority to US16/079,629 priority patent/US20210199657A1/en
Priority to JP2018544825A priority patent/JP2019511708A/ja
Priority to CA3014034A priority patent/CA3014034A1/fr
Publication of FR3048286A1 publication Critical patent/FR3048286A1/fr
Application granted granted Critical
Publication of FR3048286B1 publication Critical patent/FR3048286B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne une méthode de criblage in vitro de peptides immunogènes d'intérêt capables de reconnaitre des anticorps issus du sérum d'individus atteints de tuberculose active, ladite méthode comprenant : - la mise en contact de peptides du sérum issu de patients atteints de tuberculose active - la détection de la formation de complexes immuns à l'étape précédente, et - la sélection des peptides d'intérêt pour lesquels la valeur d'un ratio R est supérieure ou égale à 1,5, le ratio R étant la valeur de mesure de la formation de complexe immun sur la valeur de mesure obtenu à partir de l'échantillon contrôle.
FR1651610A 2016-02-26 2016-02-26 Peptides immunogenes et leur utilisation Active FR3048286B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR1651610A FR3048286B1 (fr) 2016-02-26 2016-02-26 Peptides immunogenes et leur utilisation
EP17712193.6A EP3420358A1 (fr) 2016-02-26 2017-02-24 Peptides immunogenes et leur utilisation
CN201780013116.0A CN108885213A (zh) 2016-02-26 2017-02-24 免疫原性肽和其用途
US16/079,629 US20210199657A1 (en) 2016-02-26 2017-02-24 Immunogenic peptides and use thereof
PCT/FR2017/050418 WO2017144830A1 (fr) 2016-02-26 2017-02-24 Peptides immunogenes et leur utilisation
JP2018544825A JP2019511708A (ja) 2016-02-26 2017-02-24 免疫原性ペプチド及びその使用
CA3014034A CA3014034A1 (fr) 2016-02-26 2017-02-24 Peptides immunogenes et leur utilisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1651610A FR3048286B1 (fr) 2016-02-26 2016-02-26 Peptides immunogenes et leur utilisation

Publications (2)

Publication Number Publication Date
FR3048286A1 FR3048286A1 (fr) 2017-09-01
FR3048286B1 true FR3048286B1 (fr) 2021-01-22

Family

ID=56263826

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1651610A Active FR3048286B1 (fr) 2016-02-26 2016-02-26 Peptides immunogenes et leur utilisation

Country Status (7)

Country Link
US (1) US20210199657A1 (fr)
EP (1) EP3420358A1 (fr)
JP (1) JP2019511708A (fr)
CN (1) CN108885213A (fr)
CA (1) CA3014034A1 (fr)
FR (1) FR3048286B1 (fr)
WO (1) WO2017144830A1 (fr)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
TR200806258T2 (tr) * 1995-09-01 2008-10-21 Corixa Corporation Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler
CA2758124A1 (fr) * 2008-04-19 2009-10-22 New York University Peptide de mycobacterium tuberculosis immunodominants provenant de proteines de paroi cellulaire pour un diagnostic precoce et une immunisation
US20110268744A1 (en) * 2008-05-26 2011-11-03 Ian Garthwaite Method of Diagnosis of Infection by Mycobacteria and Reagents Therefor
WO2011119484A1 (fr) * 2010-03-23 2011-09-29 Iogenetics, Llc Procédés bioinformatiques pour déterminer la liaison de peptides
WO2013040142A2 (fr) * 2011-09-16 2013-03-21 Iogenetics, Llc Procédés bio-informatiques de détermination de liaisons peptidiques
CN102297968B (zh) * 2010-06-28 2013-10-30 程小星 辅助诊断结核病的试剂盒
US9274110B2 (en) * 2011-06-03 2016-03-01 Universite Montpellier 2 Sciences Et Technique Diagnosis method of active tuberculosis
JP6317993B2 (ja) * 2014-05-07 2018-04-25 ポーラ化成工業株式会社 肌改善剤のスクリーニング方法
CN104020297B (zh) * 2014-06-10 2016-12-07 上海交通大学医学院 用于结核分枝杆菌感染检测及临床治疗效果监测的试剂盒及其用途

Also Published As

Publication number Publication date
EP3420358A1 (fr) 2019-01-02
CN108885213A (zh) 2018-11-23
CA3014034A1 (fr) 2017-08-31
JP2019511708A (ja) 2019-04-25
FR3048286A1 (fr) 2017-09-01
WO2017144830A1 (fr) 2017-08-31
US20210199657A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
McShane et al. A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data
Corstjens et al. Lateral flow assay for simultaneous detection of cellular-and humoral immune responses
Spensieri et al. Early rise of blood T follicular helper cell subsets and baseline immunity as predictors of persisting late functional antibody responses to vaccination in humans
Nogueira et al. Diagnostic biomarkers for active tuberculosis: progress and challenges
Höftberger et al. Clinical neuropathology practice guide 5-2012: updated guideline for the diagnosis of anti-neuronal antibodies
Kim et al. Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy
JP2012073273A5 (fr)
Ramberger et al. Comparison of diagnostic accuracy of microscopy and flow cytometry in evaluating N-methyl-D-aspartate receptor antibodies in serum using a live cell-based assay
Birrueta et al. Peanut-specific T cell responses in patients with different clinical reactivity
EP3112800A3 (fr) Procede de mesure d'au moins une dimension d'un objet
JP2016520846A5 (fr)
FR3048286B1 (fr) Peptides immunogenes et leur utilisation
FR3070498B1 (fr) Dispositif et procede de determination de la presence ou de l'absence et eventuellement du deplacement d'un objet contenu dans un logement
Azevedo et al. Evaluation of the double agar gel immunodiffusion test and of the enzyme-linked immunosorbent assay in the diagnosis and follow-up of patients with chronic pulmonary aspergillosis
JP2017526931A5 (fr)
Baassi et al. Evaluation of a multi-antigen test based on B-cell epitope peptides for the serodiagnosis of pulmonary tuberculosis
WO2018068064A3 (fr) Protéines de mycobacterium tuberculosis dans des dosages et dispositifs de diagnostic pour la détection et le diagnostic de la tuberculose
Henrard et al. Proportions of interferon-γ-producing ascites lymphocytes in response to mycobacterial antigens: a help for early diagnosis of peritoneal tuberculosis in a low TB incidence country
Staats et al. Development of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar typhi Vi polysaccharide
CHOI et al. CysA2: A candidate serodiagnostic marker for Mycobacterium tuberculosis infection
Bolanakis et al. On the evaluation of contemporary commercial barometric pressure sensors for altitude measurements
TW201005847A (en) Inspecting method and inspecting equipment
Zhang et al. A label-free optical biosensor for serotyping" unknown" influenza viruses
JP2019120640A (ja) 同軸度測定方法
de Oliveira Rodrigues et al. Application of Quality Statistical Tools for the Evaluation of Diagnostic Tests for SARS-CoV-2 Detection

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20170901

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8